Donate Toggle Menu

Robotic Surgery Facilitates Partial Nephrectomy

Robotic partial nephrectomy for patients with complex kidney tumors accomplishes tumor resection and renal reconstruction while minimizing warm ischemia times, claims a new study. Researchers at the United States National Cancer Institute (NCI, Bethesda, MD, USA) assessed a total of 14 tumors that were resected by robotic partial nephrectomy from eight patients (mean age 50.3 years) with complex kidney tumor features, which included hilar, completely endophytic, or multiple tumors. The results showed that the robotic partial nephrectomy procedures were performed successfully without complications. Hilar clamping was used with a mean warm ischemia time of 31 minutes; mean blood loss was 230 milliliters. Histopathology confirmed three cases of clear-cell renal cell carcinoma, two of hybrid oncocytic tumor, two chromophobe renal cell carcinomas, and an oncocytoma. Mean index tumor size was 3.6 cm, and all patients had negative surgical margins. At 3-months follow-up, no patients experienced a statistically significant change in serum creatinine or estimated glomerular filtration rate and there was no evidence of tumor recurrence. The study was published ahead of print on October 15, 2007, in the online version of European Urology. “A robotic approach can facilitate the technical challenges of laparoscopic partial nephrectomy, potentially allowing select patients to receive a minimally-invasive and nephron-sparing surgery who might otherwise receive open surgery or total nephrectomy,” said first author Dr. Craig Rogers, director of robotic kidney surgery at Henry Ford Hospital (Detroit, MI, USA). Sourc:

The burden of illness associated with renal cell carcinoma in the United States

There were over 36,000 new cases of kidney cancer reported in the United States in 2004, the most common type being renal cell carcinoma (RCC). Available treatments for localized RCC frequently lead to cure; however RCC patients with advanced disease have limited treatment options and low survival rates. Data on the economic burden of RCC are limited. Source: Urologic Oncology: Seminars and Original Investigations

Novartis plans four cancer drugs by 2011

The first new drug Novartis seeks to market is RAD001, which it is testing against several types of cancer, including endocrine tumors and renal-cell cancer, Epstein told the newspaper.

Wyeth Receives Honors at the 2007 Scrip Awards

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has been recognized for its leading scientific and pharmaceutical achievements at the third annual Scrip Awards ceremony held in London, England on December 4. Wyeth received honors for Best Overall Pipeline, and Best New Drug. The awards are given out by Scrip World Pharmaceutical News, a leading source of global business news in the pharmaceutical and biotechnology industries, in recognition of companies and products that contribute to science and human health.

Argos Therapeutics Presents Positive Data on its Personalized Cancer Immunotherapy Programs at ISTBC Meeting

Argos Therapeutics today announced the presentation of two abstracts related to its personalized dendritic cell-based immunotherapy programs at the 22nd Annual Meeting of the International Society for the Biological Treatment of Cancer (iSTBc), held November 2-4 in Boston. Results from the presented abstracts reveal that Argos’ immunotherapeutic candidate AGS-003 is compatible in combination with sunitinib (Sutent(R)) for the treatment of renal cell carcinoma (RCC).

New kidney surgery performed at Barnes Jewish

ST. LOUIS, Aug. 4, 2008 (PRIME NEWSWIRE) — Imagine cancer surgery with barely a scar to show for it. For the first time in the world, Washington University surgeons at Barnes-Jewish Hospital ( removed a large kidney cancer through a single incision at the patient’s belly button. The world’s first single incision robotic surgery (SIRS) was performed August 1 using the da Vinci(r) Surgical System in a two and a half hour procedure to remove a patient’s kidney and a tumor measured at 12 centimeters – about twice the size of the kidney itself.

1 362 363 364

Media Contact

Email Radha Chitale with media inquiries. Please include your name, outlet, topic, deadline, and contact details.

Get Our Logos